Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

111 through 120 of 326

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Update : Breast cancer disparities in Black Americans

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Most relevant for: Black women in the US

The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this review, we highlight findings on the burden of breast cancer in Black women. (posted 8/5/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Article : Overview of pancreatic cancer treatment options

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People with pancreatic cancer

This review looks at current strategies for pancreatic cancer care and potential future therapies. (posted 7/28/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Test score may predict which prostate cancer patients can safely skip combined therapy

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Men with advanced prostate cancer

This study shows that a test score that estimates the aggressiveness of a person’s prostate cancer may also identify the best treatment for patients. (posted 7/9/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Cancer risks of people with inherited PALB2 mutations

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: people with inherited PALB2 mutations

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Women can have safe pregnancies after breast cancer treatment

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women who have had breast cancer who are considering pregnancy.

In a large analysis of all published studies to date, most women who become pregnant after breast cancer treatment had safe pregnancies, with no increase in their cancer recurrence risk. Infants of mothers treated for breast cancer were more likely to have low birth weight, preterm birth and small size at birth but there was no increase in birth defects. Breast cancer survivors who became pregnant had a similar risk of recurrence and survival as survivors who did not become pregnant. (posted 6/24/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Birth control pills may offer long-term protection against endometrial and ovarian cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People concerned about endometrial, ovarian or breast cancer risk

A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)

Este artículo está disponible en español.

Read More

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Update : FDA allows testing of a vaccine designed to prevent breast cancer

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Patients with non-metastatic triple-negative breast cancer at high risk of recurrence.

Scientists have been working for many years to develop a vaccine that will prevent breast cancer. The FDA recently announced that the first clinical trial to test a preventive breast cancer vaccine can begin. This vaccine is the result of over a decade of research in animals and human cells. While researchers will first test the vaccine in women who have breast cancer, they hope to use this vaccine in the future to prevent breast cancer.  (posted 5/25/21)

THIS INFORMATION HAS BEEN UPDATED on 10/12/2021: The clinical trial discussed in this XRAY review has begun recruiting participants.  Researchers hope to enroll 24 patients with non-metastatic triple-negative breast cancer. The trial is being conducted at the Cleveland Clinic in Cleveland, Ohio. More information on this trial can be found here.

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with recurrent or advanced endometrial cancer

The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with Lynch syndrome

Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)

Este artículo está disponible en español.

Read More